The FDA has launched TEMPO (“Technology-Enabled Meaningful Patient Outcomes”), a voluntary digital health pilot program designed to expand access to certain health devices for chronic diseases while maintaining patient safety.

The program was developed by the FDA’s Center for Devices and Radiological Health (CDRH) and focuses on a new, risk-based regulatory approach for digital devices aimed at improving clinical outcomes in three major areas: cardio-renal-metabolic conditions, musculoskeletal problems, and behavioral health conditions.

The intention is to align regulatory policy with the rapid and iterative pace of digital health innovation, enabling technologies that can be used at home and in everyday settings to reach patients living with chronic diseases more quickly.

WHOM DOES IT IMPACT?

The direct impact is felt by manufacturers of devices and digital solutions for chronic diseases, regulatory bodies, and patients with cardiometabolic, musculoskeletal, and behavioral health conditions.

CONCLUSION:

TEMPO is not just another pilot program, but a strategic regulatory experiment that, if successful, could redefine how digital technologies for chronic diseases are approved, evaluated, and funded, shifting the focus to real-world data and home-based care models, with structural implications for the digital medtech industry and for chronic disease management in the US.